# Single Centre Study to Determine the Antibody Response to G17DT in Patients With Advanced Pancreatic Cancer.

> **NCT02098239** · PHASE2 · COMPLETED · sponsor: **Cancer Advances Inc.** · enrollment: 41 (actual)

## Conditions studied

- Jaundice
- Pancreatic Cancer

## Interventions

- **DRUG:** G17DT

## Key facts

- **NCT ID:** NCT02098239
- **Lead sponsor:** Cancer Advances Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-08
- **Primary completion:** 2002-04
- **Final completion:** 2002-05
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2014-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02098239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02098239, "Single Centre Study to Determine the Antibody Response to G17DT in Patients With Advanced Pancreatic Cancer.". Retrieved via AI Analytics 2026-06-21 from https://api.ai-analytics.org/clinical/NCT02098239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*